scholarly journals OC21.08: Pilot study: utilising MRI to measure cardiac function in the sheep fetus

2019 ◽  
Vol 54 (S1) ◽  
pp. 55-56
Author(s):  
K. Cho ◽  
J.R. Darby ◽  
B. Saini ◽  
M.C. Lock ◽  
S.L. Holman ◽  
...  
Keyword(s):  
Pilot Study ◽  
Cardiac Function ◽  
Sheep Fetus

scholarly journals Pilot Study: Utilising MRI to Measure Cardiac Function in the Sheep Foetus

2019 ◽  
Vol 28 ◽  
pp. S262-S263
Author(s):  
K. Cho ◽  
J. Darby ◽  
B. Saini ◽  
M. Lock ◽  
S. Holman ◽  
...  
Keyword(s):  
Pilot Study ◽  
Cardiac Function

Moderate Intensity Continuous Training versus High Intensity Interval Training in Growth Restricted Mice to Improve Cardiac Function: A Pilot Study

2020 ◽  
Vol 34 (S1) ◽  
pp. 1-1
Author(s):  
Ashley C. McPeek ◽  
Austin G. Wellette-Hunsucker ◽  
Ashley N. Triplett ◽  
Olivia Lord ◽  
William Clark ◽  
...  
Keyword(s):  
Pilot Study ◽  
Cardiac Function ◽  
High Intensity ◽  
Interval Training ◽  
Moderate Intensity ◽  
High Intensity Interval Training ◽  
Continuous Training ◽  
High Intensity Interval

Effect of azotemia on serum N-terminal proBNP concentration in dogs with normal cardiac function: A pilot study

2009 ◽  
Vol 11 ◽  
pp. S81-S86 ◽  
Author(s):  
M.K. Schmidt ◽  
C.A. Reynolds ◽  
A.H. Estrada ◽  
R. Prošek ◽  
H.W. Maisenbacher ◽  
...  
Keyword(s):  
Pilot Study ◽  
Cardiac Function ◽  
Normal Cardiac Function

scholarly journals Myocardial homing of mesenchymal stem cells following intrapericardial application and amplification by inflammation — an experimental pilot study

2017 ◽  
Vol 95 (9) ◽  
pp. 1064-1066 ◽  
Author(s):  
Nina Jung ◽  
Heinz Rupp ◽  
A. Rembert Koczulla ◽  
Claus F. Vogelmeier ◽  
Peter Alter
Keyword(s):  
Heart Failure ◽  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Stem Cell ◽  
Pilot Study ◽  
Cardiac Function ◽  
Cell Homing

Recent studies demonstrated potential effects of stem cells on cardiac function in heart failure. However, influences of the technique of application remained undetermined. In the present study, the pericardial sac was used as depot for fluorescent-labeled mesenchymal stem cells in rats. To evaluate influences of inflammation on cell homing, a sterile pericarditis was induced by talc. It is shown that intrapericardial stem cell application is sufficient to provide myocardial penetration. The extent of homing was amplified by inflammation in a talc-induced pericarditis.

scholarly journals Pentraxin 3 and retinopathy among type 2 diabetic patients in relation to carotid atherosclerosis and systolic and diastolic cardiac function — a pilot study

2018 ◽  
Vol 7 (4) ◽  
pp. 196-202 ◽  
Author(s):  
Artur Chodkowski ◽  
Katarzyna Nabrdalik ◽  
Hanna Kwiendacz ◽  
Andrzej Tomasik ◽  
Wojciech Bartman ◽  
...  
Keyword(s):  
Pilot Study ◽  
Cardiac Function ◽  
Carotid Atherosclerosis ◽  
Diabetic Patients ◽  
Pentraxin 3 ◽  
Type 2 Diabetic Patients ◽  
Type 2 Diabetic ◽  
Diastolic Cardiac Function

scholarly journals Heart rateper seimpacts cardiac function in patients with systolic heart failure and pacing: a pilot study

2009 ◽  
Vol 11 (1) ◽  
pp. 53-57 ◽  
Author(s):  
Damien Logeart ◽  
Jean-Pierre Gueffet ◽  
François Rouzet ◽  
Françoise Pousset ◽  
Christophe Chavelas ◽  
...  
Keyword(s):  
Heart Failure ◽  
Pilot Study ◽  
Cardiac Function ◽  
Systolic Heart Failure

Abstract P436: The Role of Free Fatty Acids in Patients With Obesity and Heart Failure With Preserved Ejection Fraction: A Post-hoc Analysis of the UFA-preserved Pilot Study

Circulation ◽  
2020 ◽  
Vol 141 (Suppl_1) ◽  
Author(s):  
Hayley Billingsley ◽  
Justin M Canada ◽  
ROSHANAK MARKLEY ◽  
Brando Rotelli ◽  
Dinesh Kadariya ◽  
...  
Keyword(s):  
Heart Failure ◽  
Fatty Acids ◽  
Body Composition ◽  
Pilot Study ◽  
Ejection Fraction ◽  
Cardiac Function ◽  
Free Fatty Acids ◽  
Dietary Intervention ◽  
Rank Test ◽  
Preserved Ejection Fraction

Background: Increased circulating free fatty acids (FFA) are associated with an increased risk for heart failure (HF). Interestingly, in the setting of established HF, the failing heart relies heavily on the use of FFA as energetic substrate, and therapeutics aimed at reducing FFA in HF have been found to worsen cardiac performance. A dietary intervention aimed at increasing unsaturated fatty acids (UFA) was associated with favorable changes in cardiorespiratory fitness (CRF) in patients with obesity and HF with preserved ejection fraction (HFpEF) in the UFA-Preserved Pilot Study, although the mechanism remains largely unknown. We hypothesized that dietary UFA supplementation is associated with an increase in circulating FFA and may improve determinants of CRF such as cardiac function and body composition. Methods: Eight subjects with obesity and HFpEF engaged in 12 weeks of UFA supplementation by increasing intake of foods rich in monounsaturated fatty acids (i.e., oleic acid) and polyunsaturated fatty acids (i.e., α-linolenic acid, linoleic acid) under instruction and monitoring of a research dietitian. Measures were performed at baseline and 12 weeks. Subjects underwent venipuncture to measure circulating FFA, plasma biomarkers of UFA consumption, and NT-proBNP.. Bioelectrical impedance analysis was used to estimate skeletal muscle mass (SMM). Maximal cardiopulmonary exercise testing was performed to measure CRF defined as peak oxygen consumption (VO 2 ). Data are presented as median and interquartile range. Within group changes were assessed using Wilcoxon rank test and correlations were performed using Spearman rank test. Results: Five subjects were female and median age was 53 [50-59] years. The dietary intervention resulted in a significant increase in FFA (from 0.29 [0.20-0.43] to 0.37 [0.32-0.73] μmol/L, p=0.012) and plasmatic UFA (from 1319 [1224-1477] to 1620 [1268-2110] μg/mL, p=0.05). Changes in FFA were positively associated with changes in plasmatic UFA (R=+0.74, p=0.035). Changes in FFA were associated with a trend toward improvement in peak VO 2 , although it did not reach statistical significance (R=+0.72, p=0.068). Changes in FFA were also positively and significantly associated with an increase in SMM expressed in kg (R=+0.99, p<0.001) and % of body weight (R=+0.90, p=0.006) and inversely associated with changes in NT-proBNP (R=-0.85, p=0.007). Conclusion: In patients with obesity and HFpEF, dietary UFA supplementation increases FFA, which are associated with favorable changes in cardiac function and body composition. This supports a novel mechanism through which UFA may positively affect CRF. Ongoing randomized controlled trials (NCT03966755) are underway investigating UFA supplementation as a therapeutic strategy to improve CRF in obesity and HFpEF.

Recovery of chemotherapy-induced left ventricular dysfunction in cancer survivors.

2016 ◽  
Vol 34 (3_suppl) ◽  
pp. 136-136
Author(s):  
Anecita P. Fadol ◽  
Jose Banchs ◽  
Saamir Hassan ◽  
Jean-Bernard Durand ◽  
Valerie Shelton ◽  
...  
Keyword(s):  
Pilot Study ◽  
Cardiac Function ◽  
Cancer Survivors ◽  
Left Ventricular Dysfunction ◽  
Ventricular Dysfunction ◽  
The United States ◽  
Left Ventricular ◽  
Left Ventricular Ejection ◽  
Clinical Issue ◽  
Ventricular Ejection Fraction

136 Background: Chemotherapy-induced left ventricular dysfunction (CILVD) leading to heart failure (HF) is a clinical problem of emerging importance particularly with the 14.5 million cancer survivors who are alive in the United States today, and projected to increase to almost 19 million in 2024. Many of these survivors have received cardiotoxic anticancer agents such as anthracycline and trastuzumab. Research showed that those exposed to anthracyclines are expected to have some degree of cardiac dysfunction 10 to 20 years after treatment and 5% of those patients will develop overt HF. This pilot study investigated whether cancer survivors with CILVD who achieved recovery of cardiac function will maintain their left ventricular ejection fraction (LVEF) if HF medications were discontinued. Methods: We conducted a prospective pilot study on 20 cancer survivors with history of CILVD with recovered cardiac function. HF medications were weaned off in a stepwise process per protocol. Cardiac function was monitored with LVEF measurement per echocardiography and cardiac biomarkers performed at baseline, 2, 4 and 6 months. Patients monitor their heart rate, blood pressure, and symptoms and reported changes based on set parameters. Results: Cancer survivors who maintained their LVEF after discontinuation of HF medications were younger (mean age 47.9 years SD+12.0), 65% female, 55% breast cancer survivors, with no history ofischemic heart disease, hypertension, diabetes mellitus and cardiac dysrhythmias. Chemotherapeutic agents (mean dose) used in the treatment of these patients include doxorubicin (363 mg/m2), epirubicin (527mg /m2), cyclophosphamide (5062 mg), and trastuzumab (6317 mg). There was no significant change from baseline measurements of LVEF and global longitudinal strain (GLS) of 55.1% (± 3.7) GLS of -18.3% (± 2.7) prior to weaning the HF medication to 56% (± 1.6) GLS of -18.2% (± 2.3). after complete withdrawal of HF medications. Conclusions: With the increasing number of young cancer survivors, CILVD may become a frequent clinical issue. Clearly, there is a need to examine the safety of withdrawing HF medications in cancer survivors with CILVD and if lifelong therapy with HF medications is necessary.

Sign in / Sign up

Export Citation Format

Share Document